People in the News: Bruce Carter May 03, 2012 Premium Save for later Regulus Therapeutics has appointed Bruce Carter to its board of directors. Carter is currently an independent member of the board of Immune Design and is chairman of non-profit TB Alliance. He previously served as CEO of Zymogenetics. Filed under Gene Silencing/Gene Editing RNAi miRNA Regulus Breaking News Fetal Hemoglobin Gene Regulation Study Points to Potential Therapeutic Targets Fulgent Genetics Q1 Revenues Soar on SARS-CoV-2 Testing Meridian Bioscience Fiscal Q2 Revenues Up 49 Percent Quidel Q1 Revenues More Than Double but Miss Expectations Twist Bioscience Q2 Revenues Grow 62 Percent Natera Q1 Revenues Grow 62 Percent The Scan Pfizer-BioNTech Seek Full Vaccine Approval According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine. Viral Integration Study Critiqued Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism. Giraffe Species Debate The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it. Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.